Skip to content

13F-HR filed by Sarissa Capital Management LP

Sarissa Capital Management LP filed this 13F-HR for the quarter ended 2020-09-30, filed 2020-11-16, with 11 holding rows worth $849,434,000.

Accession
0001567619-20-019849
Filed
2020-11-16
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q3 2020

A holdings report, 11 entries on the cover page, a total value of $849,434,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $849,434,000 with VALUE read as thousands by filing date, 13F file number 028-15935. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
BIOGEN INC COM09062X103Stock643,000$182,406,000thousands by filing date
JAZZ PHARMACEUTICALS PLC SHS USDG50871105Stock928,100$132,337,000thousands by filing date
ALKERMES PLCG01767105SHS7,825,000$129,660,000thousands by filing date
IRONWOOD PHARMACEUTICALS INC46333X108COMMON STOCK14,040,000$126,289,000thousands by filing date
ALEXION PHARMACEUTICALS INC015351109COM797,740$91,285,000thousands by filing date
INNOVIVA INC45781M101COM6,414,000$67,026,000thousands by filing date
Mersana Therapeutics Inc59045L106Common Stock2,837,000$52,824,000thousands by filing date
INTERCEPT PHARMACEUTICALS IN45845P108COM1,201,000$49,793,000thousands by filing date
BIOCRYST PHARMACEUTICALS INC COM09058V103Stock4,861,000$16,697,000thousands by filing date
REGULUS THERAPEUTICS INC75915K200COM NEW1,851,851$951,000thousands by filing date
MIRATI THERAPEUTICS INC60468T105COM1,000$166,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001567619-20-019849this filing2020-11-16acceptance time not in the bulk data set